Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2020

View Archived Issues

New mouse model of MLL-ENL-driven AML to understand the early stages of leukemogenesis

Discovery of amide-linked benzimidazole-benzoxaborole hybrids for the treatment of onchocerciasis

Caelum initiates phase II study of CAEL-101 in AL amyloidosis

Phase II results for pembrolizumab in patients with advanced rare cancers

miR15a-1 as a new a noninvasive biomarker for asthma

Sepsis study may yield new treatment strategies

Dead cells do tell tales

TET1 gene therapy patented by the Military Medical Institute Academy

How lung tumors seed to brain

Roche synthesizes new TLR7/TLR8/TLR9 antagonists

Medshine Discovery discovers drugs targeting protein cereblon

New geranylgeranyl transferase type 1 inhibitors identified at Bayer

Abbisko Therapeutics identifies new fibroblast growth factor receptor inhibitors

Investigators describe biomarkers of liver injury

Gimsilumab completes phase I study in development of gimsilumab for COVID-19-related ARDS

NGM studies NGM-395 in obese adults and patients with NAFLD

New Chinese phase I study evaluates Ad5-nCoV coronavirus vaccine

Lundbeck discontinues foliglurax program in Parkinson's following phase IIa results

FDA approves new intravenous formulation of Triferic

Lundbeck reports phase IIa results with Lu-AG06466 in Tourette's syndrome

FDA approves Imfinzi as first-line treatment for extensive-stage SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...